Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease.
Desai
Alka A
AA
Marks
Daniel J B
DJ
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007167:Immunotherapy; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology*; D012306:Risk; D055502:Secondary Prevention; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha